FOLD Amicus Therapeutics, Inc.
Healthcare$14.49+0.00%ClosedMarket Cap: $4.55B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
16.33
P/S
7.17
EV/EBITDA
89.56
DCF Value
$-29.29
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-12.0%
ROA
-2.9%
ROIC
-645.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $185.2M | 84.6% | $15.9M | $1.7M | $— | — |
| FY null | $634.2M | 87.3% | $34.5M | $-27.1M | $— | — |
| Q3 null | $169.1M | 87.4% | $34.3M | $17.3M | $— | — |
| Q2 null | $154.7M | 90.2% | $-9.5M | $-24.4M | $— | — |
| Q1 null | $125.2M | 90.7% | $-8.0M | $-21.7M | $— | — |
| Q4 null | $149.7M | 90.1% | $16.0M | $14.7M | $— | — |
| FY null | $528.3M | 90.0% | $24.9M | $-56.1M | $— | — |
| Q3 null | $141.5M | 90.6% | $21.7M | $-6.7M | $— | — |
| Q2 null | $126.7M | 91.1% | $15.0M | $-15.7M | $— | — |
| Q1 null | $110.4M | 87.7% | $-27.7M | $-48.4M | $— | — |
| Q4 2023 | $115.1M | 90.2% | $-3.7M | $-33.8M | $-0.12 | — |
| FY null | $399.4M | 90.7% | $-77.2M | $-151.6M | $— | — |